Sharemaestro Newsreel

Barclays Maintains Forte Biosciences(FBRX.US) With Hold Rating, Maintains Target Price $77

Barclays has reiterated its 'Hold' rating on Forte Biosciences (FBRX.US) and maintained its target price at $77. This indicates that the financial institution sees the stock performing in line with the broader market and expects its value to remain stable at the specified price …

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

Levi & Korsinsky has announced an investigation into Ardelyx (ARDX) following a significant 17.86% stock drop on August 7, 2026. This decline occurred after the company reported second-quarter 2026 product revenue and earnings per share that were below consensus estimates, and subsequently lowered its …

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position

Farallon Capital Management and its affiliated funds have disclosed a beneficial ownership of 10,282,210 shares of Beam Therapeutics (BEAM) common stock, representing 9.99% of the outstanding class. This position includes directly held shares and common stock purchase warrants, with exercisability capped at 9.99% due …

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn …

CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects.

CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) has shown promising results in treating non-muscle invasive bladder cancer (NMIBC), achieving a 75% complete response rate and demonstrating a best-in-class safety profile with no severe adverse events. The company plans to submit a Biologics License Application …

Why Absci (ABSI) Is Up 14.0% After Positive Early ABS-201 Hair Loss Data And Endometriosis Plans

Absci Corporation's stock (ABSI) rose 14.0% after reporting positive interim Phase 1 results for ABS-201, a drug targeting pattern hair loss, showing favorable safety and tolerability. The company also announced plans to advance ABS-201 to Phase 2 testing for endometriosis in late 2026. This …

Capricor Therapeutics Faces Securities Lawsuit

Capricor Therapeutics (NASDAQ: CAPR) is facing a federal securities class action lawsuit alleging that the company made misleading statements regarding the regulatory prospects of its investigational cell therapy, deramiocel, for Duchenne muscular dystrophy. The lawsuit centers on alleged undisclosed changes to statistical analysis plans …

Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) has announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, aiming to raise approximately $80.5 million in gross proceeds. The offering is expected to close on August 17, 2026, with …

Nektar Therapeutics Q2 Earnings Call Highlights

CG Oncology Stock: Circling Back After Huge Rally (NASDAQ:CGON)

MediciNova (NASDAQ:MNOV) Announces Quarterly Earnings Results

MediciNova (NASDAQ:MNOV) exceeded quarterly earnings expectations, reporting a loss of $0.05 per share against an estimated $0.06 loss, and revenues of $0.46 million, significantly above the $0.07 million forecast. Despite the positive earnings surprise, the company experienced a slight dip in share price to …

MeiraGTx (NASDAQ:MGTX) Releases Quarterly Earnings Results, Beats Expectations By $2.17 EPS

Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter

Earnings Call Insights: Daré Bioscience (DARE) Q2 2026 MANAGEMENT VIEW * "In June, we launched Flora Sync LF5, the first product in our DARE to RESTORE line." (CEO, President, Principal Financial Officer, Secretary & Director Sabrina Johnson) * "At the same time, we continued …

Cue Biopharma, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Cue Biopharma, Inc. (CUE) on August 14, 2026. The filing indicates a proposed sale of 8,829 shares of common stock with an aggregate market value of $266,106.06, acquired through Restricted Stock Units vesting under …

Richard Griffiths (SLN) reports 14.39M-share beneficial stake in Silence Therapeutics

Richard Griffiths has updated his beneficial ownership in Silence Therapeutics plc, reporting a 7.97% stake, or 14,391,498 ordinary shares. This amendment (Amendment No. 11) reflects significant dilution due to an increase in the issuer's share capital and includes the sale of 5,484,320 ADSs by …

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT)

Two healthcare companies, Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT), recently received bullish ratings from analysts. Myles Minter from William Blair reiterated a Buy rating for Alto Neuroscience, with a consensus price target of $35.71. Jonna Kim from TD Cowen also reiterated a Buy …

X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026)

This article reports on an SEC Form 144 filing by X4 Pharmaceuticals, Inc. (XFOR) on August 13, 2026. The filing indicates a proposed sale of 24,576 shares of common stock with an aggregate market value of $111,943.68, acquired through restricted stock unit vesting. The …

MediWound (NASDAQ:MDWD) Issues Earnings Results

Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Pyxis Oncology (NASDAQ:PYXS) reported a quarterly loss of $0.40 per share, missing analysts' consensus estimates by $0.06. The stock traded down to $3.01 with a market capitalization of $190.68 million, but analyst sentiment remains a "Moderate Buy" with a $7.50 target price. Institutional investors …

Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …

Xenon Pharmaceuticals Director Sold Shares Worth Over $640K

Steven Gannon, a Director at Xenon Pharmaceuticals (XENE), reported the sale of common shares totaling $640,550 on August 11, 2026. The transactions were executed at a weighted-average price of $64.055 per share. Following this sale, Gannon directly holds 1,870 common shares in the company.

Tango Therapeutics (TNGX) Is Getting Fresh Attention, What Are Investors Looking At?

Tango Therapeutics (TNGX) recently saw investor attention due to a wider Q2 net loss, the cessation of collaboration revenue, and a new US$400 million at-the-market equity offering which could dilute shareholders. Despite short-term share price drops, the stock shows strong momentum over longer periods, …

MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

MiNK Therapeutics (NASDAQ:INKT) reported a quarterly EPS loss of $0.62, missing analyst estimates by $0.02. The company advanced its agenT-797 treatment into a randomized Phase II ARDS trial, with preliminary data expected in the first half of 2027, and launched a paid named-patient access …

(XNCR) as a Liquidity Pulse for Institutional Tactics

This article analyzes Xencor Inc. (NASDAQ: XNCR) based on AI models, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored …

Verrica (VRCA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jayson RiegerChief Medical Officer - Noah RosenbergInterim Chief Financial Officer - John KirbyChief Operating Officer - David ZawitzChief Commercial Officer - Chris …

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.16 EPS

Edesa Biotech (NASDAQ:EDSA) reported a quarterly loss of $0.60 per share, missing analyst expectations by $0.16. Shares traded up $0.13 to $5.43, with a highly volatile one-year range of $0.72 to $20.32. Institutional investors own 5.50% of the stock, and analyst ratings are mixed, …

Equillium (NASDAQ:EQ) Announces Earnings Results

Cibus updates Latin America rice launch to 2028 while outlining $20M-$40M biofragrance revenue opportunity

Earnings Call Insights: Cibus, Inc. (CBUS) Q2 2026 MANAGEMENT VIEW * CEO Craig Wichner framed his priorities around scaling revenue and tighter spending control, saying, "I accepted the job of CEO because I believe we can generate revenue at scale. That is my mission." …

Invivyd earnings missed by $0.03, revenue fell short of estimates

Invivyd (NASDAQ: IVVD) reported second-quarter EPS of $-0.140, missing analyst estimates by $0.03, and revenue of $14.29M, falling short of the $15.64M consensus. The company's stock price has declined by -43.310% over the last three months and -2.980% over the last twelve months. Despite …

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …

Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million

Cadrenal Therapeutics (NASDAQ: CVKD) reported a Q2 2026 net loss of $3.3 million, an improvement from $3.7 million in the prior year, primarily due to reduced R&D expenses. The company ended the quarter with $2.4 million in cash, which increased to $4.2 million in …

Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN) reported a quarterly loss of $0.27 per share, missing the consensus estimate by $0.11. The stock subsequently fell 1.9% to $3.70, with a consensus "Hold" rating and an average price target of $9.67 from analysts. Institutional investors hold a significant portion …

Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares

Altimmune Inc.'s President and CEO, Jerome Durso, recently purchased 15,000 shares of the company's stock, increasing his direct ownership to 62,500 shares. This transaction is part of a larger trend of insider buying at Altimmune, with 11 insider buys and no sells in the …

Dare Bioscience earnings beat by $0.11, revenue topped estimates

Dare Bioscience (NASDAQ: DARE) reported Q2 EPS of $-0.2000, surpassing analyst estimates by $0.11, and revenue of $187.55K, significantly beating the consensus estimate of $1.67K. Despite the positive earnings surprise, the company's stock has seen a decline of -36.87% over the last three months …